TY - JOUR
T1 - Circulating, Imaging, and Genetic Biomarkers in Cardiovascular Risk Prediction
AU - Ge, Yin
AU - Wang, Thomas J.
N1 - Funding Information:
Dr. Wang has participated on the scientific advisory board of Diasorin, Inc., and has received assay support or research funding from Siemens, Brahms, Critical Diagnostics, Singulex, Diasorin, Pfizer, Roche, and LabCorp. Dr. Wang has received honoraria from Roche, Diasorin, and Quest Diagnostics. Dr. Wang is named as a co-inventor on patent applications relating to the use of metabolomic or neurohormonal biomarkers in risk prediction.
PY - 2011/5
Y1 - 2011/5
N2 - In the primary prevention of cardiovascular disease, the study of biomarkers to identify at-risk individuals is an expanding field. Several developments have fueled this trend, including improved understanding of the pathophysiological processes underlying atherosclerosis, advances in imaging technology to enable the quantification of subclinical disease burden, and the identification of new genetic susceptibility variants for cardiovascular disease. Furthermore, the advent of high-throughput platforms for molecular profiling has increased the pace of biomarker discovery. The rising interest in biomarkers has been balanced by the recognition that standardized and rigorous statistical approaches are needed to evaluate the clinical utility of candidate risk markers. This article reviews the issues surrounding the evaluation of biomarkers, evidence from studies of existing biomarkers, and recent applications of biomarker discovery platforms.
AB - In the primary prevention of cardiovascular disease, the study of biomarkers to identify at-risk individuals is an expanding field. Several developments have fueled this trend, including improved understanding of the pathophysiological processes underlying atherosclerosis, advances in imaging technology to enable the quantification of subclinical disease burden, and the identification of new genetic susceptibility variants for cardiovascular disease. Furthermore, the advent of high-throughput platforms for molecular profiling has increased the pace of biomarker discovery. The rising interest in biomarkers has been balanced by the recognition that standardized and rigorous statistical approaches are needed to evaluate the clinical utility of candidate risk markers. This article reviews the issues surrounding the evaluation of biomarkers, evidence from studies of existing biomarkers, and recent applications of biomarker discovery platforms.
UR - http://www.scopus.com/inward/record.url?scp=84861905041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861905041&partnerID=8YFLogxK
U2 - 10.1016/j.tcm.2012.03.007
DO - 10.1016/j.tcm.2012.03.007
M3 - Review article
C2 - 22681965
AN - SCOPUS:84861905041
SN - 1050-1738
VL - 21
SP - 105
EP - 112
JO - Trends in Cardiovascular Medicine
JF - Trends in Cardiovascular Medicine
IS - 4
ER -